Patients
ABO-compatible
R12
From Aug 2015 to Feb 2017, 14 patients and their respective donors were screened for inclusion in the TOL-1 study. Ten patients eventually received MIC intravenously on the day of donor leukapheresis as a single administration as described previously (group A, patient R1-R3: low dose MIC on day -2; group B, patient R4-R6: high dose MIC on day -2; group C, patient R7, R11, R12, R14: high dose MIC on day -7 before surgery; Follow-up of the TOL-1 study and selection of transplanted controls (modified from reference 14 and 15). The control group consisted of adult living donor kidney transplant recipients at the same immunologic risk, i.e., ABO-compatible and non-sensitized, who received the same immunosuppressive maintenance therapy, i.e., CyA, EC-MPS, and corticosteroids, and who had sufficient follow-up. Overall, 15 patients transplanted during the same period met these criteria (Baseline patient characteristics are summarized in Baseline patient characteristics (modified from references 
